Galenica locks in mid- and long-term financing at attractive conditions with the issuance of bonds

Bern, (PresseBox) - Galenica today issued fixed-interest bonds totalling CHF 380 million for the purpose of long-term financing at attractive conditions. The issue is to refinance the bridge loan granted in the course of the IPO. Galenica has taken this step in order to take advantage of the favourable capital market condi-tions to lock in medium and long-term financing at attractive conditions.

The bonds attracted strong demand across a broad spectrum of investors (largely institutional clients). The issue consists of two tranches: an intermediate tranche of CHF 200 million at 0.50% coupon maturing after 6 years in June 2023 and a longer tranche of CHF 180 million at 1.00% coupon maturing after 9 ½ years in December 2026.

The banks responsible for this transaction were Credit Suisse as lead manager and bookrunner, and Zürcher Kantonalbank as lead manager. An application for admission to trading on the SIX Swiss Exchange for the bonds is being made.

Galenica AG

Galenica is the leading fully integrated healthcare provider in Switzerland. With nearly 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of pre-wholesale and wholesale distribution as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning Galenica can be found at

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.